SEC Filing Summary: Aziyo Biologics, Inc. (AZYO)
Business Context and Reporting Period
This Form 8-K was filed by Aziyo Biologics, Inc. on November 16, 2021. The company is incorporated in Delaware and its Class A Common Stock trades on the Nasdaq Global Market under the symbol "AZYO". The filing addresses a regulatory notice received from Nasdaq regarding continued listing standards.
Key Financial Metrics
The filing references the company's Quarterly Report on Form 10-Q for the period ended September 30, 2021. Based on that report, the company's stockholders' equity was below the $10.0 million threshold required for continued listing on the Nasdaq Global Market under Rule 5450(b)(1)(A). The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt.
Material Changes and Listing Status
On November 16, 2021, Aziyo Biologics received a written notice from Nasdaq stating it failed to meet the minimum stockholders' equity requirement. The notice has no immediate effect on the trading of the company's stock. The company has 45 days to submit a plan to regain compliance or may apply to transfer to the Nasdaq Capital Market tier. Management currently intends to transfer to the Capital Market tier.
Outlook, Risks, and Management Commentary
Management has indicated an intention to transfer listing from the Nasdaq Global Market to the Nasdaq Capital Market, subject to satisfying the Capital Market's listing requirements. The primary risk identified is the potential failure to regain compliance with Nasdaq listing standards within the allotted timeframe, which could result in delisting.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the quarter ended September 30, 2021.
- Confirm the company's progress in meeting Nasdaq Capital Market listing requirements.
- Monitor for any subsequent filings regarding the submission of a compliance plan or the formal transfer of listing.
- Review the company's liquidity position to assess its ability to fund operations while addressing the listing deficiency.